-
Views
-
Cite
Cite
A Samanta, M R Afzal, L Derbas, S S Taduru, S D Roy, V Jeevanantham, B Dawn, P4646
Bone marrow cell therapy in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials, European Heart Journal, Volume 39, Issue suppl_1, August 2018, ehy563.P4646, https://doi.org/10.1093/eurheartj/ehy563.P4646 - Share Icon Share
Extract
Introduction: Bone marrow cells (BMCs) have been utilized in numerous randomized clinical trials (RCTs) for repair of infarcted myocardium in patients with acute myocardial infarction (AMI). Although several studies have shown a modest but significant benefit, a few studies observed no significant benefit. The true extent of improvement of cardiac function and remodeling following cell injection remains unclear.
Purpose: We aimed to assess the impact of BMC therapy on left ventricular (LV) parameters in patients with AMI.
Methods: We performed a systemic review and meta-analysis of data from published RCTs that evaluated the efficacy of BMCs in patients with AMI. Database searches through May 31, 2017 identified 41 studies enrolling 2696 patients. We analyzed the effects of cell injection on LV ejection fraction (LVEF), LV end-systolic volume (LVESV), LV end-diastolic volume (LVEDV) and infarct scar size. Changes in outcomes of interest were analyzed with random-effects meta-analysis.
Results: Compared with standard therapy, BMC therapy improved LVEF (2.55%; 95% confidence interval [CI]: 1.54 to 3.55; P<0.00001) and reduced the infarct scar size (-2.01%; 95% CI: -3.08 to -0.94; P=0.0002) in patients with AMI. BMCs also reduced LVESV (-5.42 ml; 95% CI: -7.73 to -3.12; P<0.00001) and LVEDV (-2.57 ml; 95% CI: -4.79 to -0.36; P=0.02) when compared with standard therapy.